Showing posts with label Lilly. Show all posts
Showing posts with label Lilly. Show all posts

Tuesday, January 24, 2017

Five Weeks at Eli Lilly: A Non-Traditional Experience

Posted by Unknown at Tuesday, January 24, 2017

With the majority of my clinical experiences under my belt, come October it was time to drive the four hours to Indianapolis to begin my rotation at one of the world’s largest pharmaceutical companies.

Lilly, like most large companies, specializes in a handful of therapeutic areas: oncology (gemcitabine, pemetrexed, cetuximab, among others), neuroscience (the largest Alzheimer's development program on Earth), diabetes (Humalog, Humalin), and bio-medicines. The Bio-medicines unit covers a handful of smaller focus areas, including men's health, cardiovascular, pain, and others. While they have a global presence, their headquarters in Indianapolis also houses most of their production facilities, which I will discuss more later. For more background on Lilly, here is their Wikipedia page.

I had no idea what to expect going in--my preceptor is a clinical research scientist in Early Phase Oncology Clinical Development. I would quickly discover what that means!

Day 1:

I stayed about 20 minutes from Lilly's technology campus (about a 10 minute drive from their headquarters) at a friend's house whose family generously offered to allow me to stay with them (great coincidence!). The day began with a few hours of onboarding (filling out paperwork, safety training, etc.) after which I drove to the main campus to meet my preceptor.

All of the buildings on the main campus are connected underground, including the parking garages! The campus is massive--with restaurants, dry cleaning, a bank, a gym, track, and soccer fields, and other amenities on-site. We spent most of the morning discussing my preceptor's role and where I would be fitting in. It breaks down like this:

My preceptor is a clinical research scientist. As a PharmD in this role, he is responsible for the day-to-day operations of his clinical trials. This could mean ensuring enrollment is on-track, monitoring incoming safety and efficacy data (blinded!), and importantly, answering clinical questions from the providers at the research sites regarding eligibility, enrollment, side-effects, clinical management, and anything and everything in between for any of the sites scattered around the world.

Outside of the Phase III trial he is responsible for, he is required to put on his early phase hat from time to time. This might mean working with the pre-clinical development group to identify promising leads or providing recommendations for unmet medical needs that could drive a new project, authoring study reports, protocol, or manuscripts, or designing trials. This is a role with an incredible diversity of responsibilities and work types--perfect for precepting a student!

Day 2 and Beyond:

Typical days worked like this: I could arrive anywhere between 6 and 9 AM, staying until 3 to 6 PM. I was issued a company laptop that allowed me to work from home provided I had no in-office responsibilities (though I always cleared these days with my preceptor). I opted to arrive early and leave early to avoid the minimal traffic that Indianapolis developed along my route.

The work environment is highly interdisciplinary and they use an open-office environment. With your laptop you can sit more-or-less wherever you would like, lock into a dock (with a large screen and peripherals) and work there all day or move around. Few people have permanent desks but there is tons of space to sit a group around a table, and space to work alone for a while if you need to as well. I was struck by walking down the halls and overhearing conversations by engineers, pharmacists, statisticians, physicians, PhDs of all flavors, and more!

My major projects could be summarized as follows:

Safety Monitoring or Other Reporting:

As I have a computer science background, I asked for data-centric projects where possible. I was routinely given blocks of data to crunch and provide recommendations. Usually, this was blinded adverse event data from a trial. With pivot tables and a little VBA these usually went quickly. Other reporting included analyzing concomitant medications and correlating those with outcomes, or doing demographic breakdowns for relevant groups. Notably, one project had me examine the different subtypes of cancers in these trials and examine the rates and locations of metastasis and correlate these with other relevant biomarkers--are there patterns? Are these in-line with literature, if it exists? Clinical trials are valuable sources of medical knowledge even outside the medication they are testing--we've learned a lot!

Medical Information and Writing

A major responsibility of the CRS is medical writing--whether that be trial manuscripts, clinical study reports (a data summary of a clinical trial), or communication with healthcare providers. I was tasked with authoring a manuscript for a Phase I dose-escalation trial that had not yet made it to publication. I had the opportunity to dig deep into a clinical study report, learn a disease-state inside and out, and work with the primary investigators (physicians and pharmacists) to report what they had found. When I left, the study was squarely in the hands of the medical writers who were polishing and editing the final draft!

As part of the CRS role, my preceptor received anywhere from 5-10 eligibility or clinical questions from the research sites worldwide. He passed many of them on to me, where I was responsible for evaluating their question, examining the protocol and literature where appropriate, providing a recommendation, and drafting a response.

Protocol Authorship

My final major project was built around a handful of pre-clinical compounds that Lilly had been working on for some time. They targeted a genetic mutation that is believed to drive the growth of several cancers. It was left to me to examine the literature and define where the greatest unmet medical need existed; meaning which cancers lack available treatments and have high rates of mortality (e.g. pancreatic cancer) versus a cancer that the mutation might be less common in, or the cancer has powerful existing therapies available. This was much more complicated that I initially expected, given that even identifying people with the mutation consistently was a problem. What assays should we use and how do they work? There were over a dozen methods that were not correlated with each other, and then attempting to work out how they correlated with outcomes was another hurdle.

This culminated in authoring a protocol synopsis: taking everything I had learned and transforming that into a study summary including information like: what cancers, who are we targeting, how do we identify them? What inclusion and exclusion criteria should be used to that effect? What are the treatments we'll use? What study design? What endpoints will be used and how are they measured? And much, much more!

Other

Lastly, Lilly has a structured program for visiting P4 students where you will meet dozens of practicing pharmacists from roles all over the company. There were usually 2 or 3 weekly, plus any other one-on-one meetings that you could schedule anywhere you'd like. One of the pharmacists works in the manufacturing facility, so we got a tour and saw how many of their drugs are made! Incredible to see!

I had a wonderful time at Lilly, and now there are even more opportunities to go! I hope this gives you a good idea of what I did while I was there--I definitely learned that this is where I want to end up!

Michael Harrison (mhar)




Wednesday, September 14, 2011

Oncologic Drugs Advisory Committee

Posted by Eric Zhao at Wednesday, September 14, 2011

SILVER SPRING, Maryland - Oncology experts from around the nation gather in the FDA's White Oak Conference Center to evaluate the new drug application for Ferriprox (deferiprone) and to discuss trial design for the development of products to treat patients with non-metastatic prostate cancer. It's 8 o'clock in the morning and the Chair of the Oncologic Drugs Advisory Committee (ODAC) meeting begins the Call to Order for this all-day meeting. The ODAC consists of 13 voting members to review and evaluate safety and efficacy data for oncology drugs and makes recommendations to the Commissioner of Food and Drugs, CDER, and CBER.

Their view:


The Great Room in the White Oak Conference Center
FDA White Oak Campus, Building 31

Meanwhile, in Indianapolis, I park myself in my desk chair, log on to the Lilly corporate system, and break out my headphones. Inside my bag, I pack two caffeinated beverages with my lunch to prepare for today's 8:00 a.m. to 5:00 p.m. meeting. My assignment today consists of analyzing and interpreting how the FDA thinks. Think of it like the industry playing chess against the FDA.

My view:


The closed captioning didn't make sense all day.

Ferriprox (deferiprone) [8:00 a.m. - 12:00 p.m.]


Iron Man's Kryptonite

Submitted by ApoPharma, Inc., deferiprone is proposed for the treatment of patients with transfusional iron overload, when current chelation therapy is inadequate. During the meeting, ApoPharma, Inc. presents their case, and then afterwards, the FDA presents their case (are we in court??). Following this, the public delivers their testimonials and opinions about the magic of deferiprone. Finally, the ODAC answers questions, discusses any issues, and casts a final vote. In this case, they voted 10-2 to support an application for accelerated approval.

Non-Metastatic Prostate Cancer Study Design [1:00 p.m. - 5:00 p.m.]
Currently, there are no products approved for the following indications:
  1. Non-metastatic, PSA-only recurrent prostate cancer who have not received androgen deprivation therapy (ADT)
  2. Non-metastatic castration resistant prostate cancer (NM-CRPC) who have a rising serum level of prostate-specific antigen (PSA) despite currently receiving ADT
The afternoon session of the ODAC meeting discusses possible patient populations, trial designs, and suitable clinical endpoints for studies intended to support a product for these unmet medical needs. The session begins with an FDA presentation and two speaker presentations for background, and I feel like I'm in lecture again. For the next 3 hours, however, the committee argues about the pros and cons of trial endpoints until they finally hit 5:00 p.m.--with a split conclusion. I'm sure my preceptor is going to loooove this result.

The Food and Drug Administration


FDA stands for Full Day Agenda

Today was definitely a test of endurance, but a great experience nonetheless. I wish I requested a clerkship rotation with the FDA, because after attending this meeting, I realize how valuable that experience would have been. If you're interested in the industry, having been at the FDA will truly give you a leg up. Write that down...

-Eric Zhao

Friday, September 2, 2011

Caught Up In The Regulations

Posted by Eric Zhao at Friday, September 02, 2011

Once again, I find myself in the pharmaceutical industry (surprise!). This time, however, I am with Eli Lilly and Company...in the Regulatory Affairs Department, no less.


Eli Lilly and Company, Indianapolis, IN

If you remember from my previous adventures, I spent a summer in regulatory affairs at Abbott in Advertising and Promotion. You're probably thinking, what's the point of doing two regulatory affairs positions? I had the same thought, believe me.

What I didn't know was that I would be working on the complete opposite spectrum of the drug development process. At Abbott, I dealt with the regulations after the FDA approved a drug. At Lilly, I deal with the regulations before and during FDA approval. Yup, I'm working with Investigational New Drug (IND) applications and New Drug Applications (NDA).

I'm currently wrapping up a journal club presentation for this upcoming Tuesday on a competitor's newly approved biologic drug and will finish the rest of the clerkship gathering intelligence on a project that's under Double Secret Probation. I wish I could say more, but these industry folk like to keep to themselves.

I'm sure I'll come up with interesting topics to blog about that won't compromise my employment status, but for now, enjoy a picture of Lilly's entrance fountain.



Best,
Eric